Colorectal Cancer Immunotherapy: State of the Art and Future Directions
Alyssa Mauri Cornista, Maria Virginia Giolito, Kristi Baker, Hajar Hazime, Inès Dufait, Jashodeep Datta, Saratchandra Singh Khumukcham, Mark De Ridder, Jatin Roper, María T. Abreu, Karine Breckpot, Kevin Van der Jeught
Abstract
Cancer immunotherapy has become an indispensable mode of treatment for a multitude of solid tumor cancers. Colorectal cancer (CRC) has been one of the many cancer types to benefit from immunotherapy, especially in advanced disease where standard treatment fails to prevent recurrence or results in poor survival. The efficacy of immunotherapy in CRC has not been without challenge, as early clinical trials observed dismal responses in unselected CRC patients treated with checkpoint inhibitors. Many studies and clinical trials have since refined immunotherapies available for CRC, solidifying immunotherapy as a powerful asset for CRC treatment. This review article examines CRC immunotherapies, from their foundation, through emerging avenues for improvement, to future directions.